Derleme

Recent advances in boron containing anticancer drug delivery nanocarrier platforms

Cilt: 11 Sayı: 3 30 Eylül 2026
PDF İndir
TR EN

Recent advances in boron containing anticancer drug delivery nanocarrier platforms

Öz

Boron-containing compounds have emerged as versatile building blocks in the design of advanced anticancer drug delivery systems due to their unique chemical features, including electron deficiency, reversible covalent interactions, and structural diversity. In recent years, significant progress has been made in engineering boron-functionalized nanocarriers to enhance tumor targeting, improve drug loading efficiency, and achieve controlled release while minimizing systemic toxicity. This review highlights recent advances in boron-containing anticancer drug delivery nanoplatforms, including boron-nitride nanoparticles, boronic acid-functionalized polymers, BODIPY-based nanocarriers and boron incorporated supramolecular nanoplatforms. Particular attention is given to stimulus-responsive systems exploiting the dynamic covalent interactions between boronic acids and cis-diols for pH-, ligand-, or reactive oxygen species-triggered drug release in the tumor microenvironment. Strategies to improve cellular uptake, enhance intracellular stability, and achieve selective cytotoxicity are also discussed. Furthermore, multifunctional nanocarriers incorporating imaging capabilities or combinatorial therapeutic modalities are examined. Despite promising preclinical results, challenges remain in large-scale production, long-term biosafety evaluation, pharmacokinetic optimization, and clinical translation. Overall, boron- containing nanocarriers represent a rapidly evolving platform with strong potential to advance targeted and responsive anticancer drug delivery.

Anahtar Kelimeler

Kaynakça

  1. Fink, H., Langselius, O., Vignat, J., Rumgay, H., Rehm, J., Martinez, R. X., … & Soerjomataram, I. (2026). Global and regional cancer burden attributable to modifiable risk factors to inform prevention. Nature Medicine, 32(4), 1306-1315. https://doi.org/10.1038/s41591-026-04219-7
  2. Jung, Y., Longo, C., & Tompa, E. (2022). Longitudinal assessment of labor market earnings among patients diagnosed with cancer in Canada. JAMA Network Open, 5(12), e2245717-e2245717. https://doi.org/10.1001/JAMANETWORKOPEN.2022.45717
  3. McKeague, B., & Maguire, R. (2021). “The effects of cancer on a family are way beyond the person who’s had it”: The experience and effect of a familial cancer diagnosis on the health behaviours of family members. European Journal of Oncology Nursing, 51, 101905. https://doi.org/10.1016/J.EJON.2021.101905
  4. Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025). Advancements and limitations in traditional anti-cancer therapies: A comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discover Oncology, 16(1), 607. https://doi.org/10.1007/S12672-025-02198-8
  5. Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., … & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. Heliyon, 9(6), e17488. https://doi.org/10.1016/J.HELIYON.2023.E17488
  6. Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S. (2025). Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects. European Journal of Medicinal Chemistry, 290, 117535. https://doi.org/10.1016/J.EJMECH.2025.117535
  7. Zhang, X., Liu, W., Chu, H., & Zong, W. (2026). Liposomes: A breakthrough in advanced drug delivery systems. Advances in Colloid and Interface Science, 353, 103887. https://doi.org/10.1016/J.CIS.2026.103887
  8. Papavasileiou, E. Z., Rekkas, D. M., Dallas, P. P., Pispas, S., & Pippa, N. (2026). Unlocking the potential of micelles: DoE and QbD strategies for formulation development and optimization. Journal of Drug Delivery Science and Technology, 115, 107795. https://doi.org/10.1016/J.JDDST.2025.107795

Ayrıntılar

Birincil Dil

İngilizce

Konular

Malzeme Mühendisliği (Diğer)

Bölüm

Derleme

Yayımlanma Tarihi

30 Eylül 2026

Gönderilme Tarihi

2 Mayıs 2026

Kabul Tarihi

23 Temmuz 2026

Yayımlandığı Sayı

Yıl 2026 Cilt: 11 Sayı: 3

Kaynak Göster

APA
Nakipoğlu, M. (2026). Recent advances in boron containing anticancer drug delivery nanocarrier platforms. Journal of Boron, 11(3), 218-242. https://doi.org/10.30728/boron.1942518
AMA
1.Nakipoğlu M. Recent advances in boron containing anticancer drug delivery nanocarrier platforms. Journal of Boron. 2026;11(3):218-242. doi:10.30728/boron.1942518
Chicago
Nakipoğlu, Mustafa. 2026. “Recent advances in boron containing anticancer drug delivery nanocarrier platforms”. Journal of Boron 11 (3): 218-42. https://doi.org/10.30728/boron.1942518.
EndNote
Nakipoğlu M (01 Eylül 2026) Recent advances in boron containing anticancer drug delivery nanocarrier platforms. Journal of Boron 11 3 218–242.
IEEE
[1]M. Nakipoğlu, “Recent advances in boron containing anticancer drug delivery nanocarrier platforms”, Journal of Boron, c. 11, sy 3, ss. 218–242, Eyl. 2026, doi: 10.30728/boron.1942518.
ISNAD
Nakipoğlu, Mustafa. “Recent advances in boron containing anticancer drug delivery nanocarrier platforms”. Journal of Boron 11/3 (01 Eylül 2026): 218-242. https://doi.org/10.30728/boron.1942518.
JAMA
1.Nakipoğlu M. Recent advances in boron containing anticancer drug delivery nanocarrier platforms. Journal of Boron. 2026;11:218–242.
MLA
Nakipoğlu, Mustafa. “Recent advances in boron containing anticancer drug delivery nanocarrier platforms”. Journal of Boron, c. 11, sy 3, Eylül 2026, ss. 218-42, doi:10.30728/boron.1942518.
Vancouver
1.Mustafa Nakipoğlu. Recent advances in boron containing anticancer drug delivery nanocarrier platforms. Journal of Boron. 01 Eylül 2026;11(3):218-42. doi:10.30728/boron.1942518